Answers are grounded in this paper and cite their sources.
The study by Vaz et al. published in Brain in 2019 established a novel firm link between disrupted etherlipid biosynthesis and complex forms of hereditary spastic paraplegia (HSP) through the identification of recessive mutations in the PCYT2 gene (Synofzik and Schule, 2017; Darios et al., 2020; Rickman et al., 2020). Before, genetic causes of HSP had been found in genes with diverse functional roles (Shribman et al., 2019) including chaperone activity, axonal transport, mitochondrial function and many others. However, mutations in genes involved in complex lipid metabolism have increasingly been implicated in the pathology of HSP (CYP7B1, CYP2U1, DDHD1, DDHD2, BSCL2, ERLIN2, FA2H and PNPLA6/NTE, SELENOI/EPT1, SERAC1) (Windpassinger et al., 2004; Rainier et al., 2008; Goizet et al., 2009; Alazami et al., 2011; Schuurs-Hoeijmakers et al., 2012; Tesson et al., 2012; Cao et al., 2013; Synofzik et al., 2014; Ahmed et al., 2017; Roeben et al., 2018), thus presenting a converging and possibly even treatable mechanistic theme in pathophysiology of manifold HSP and spastic ataxias (Synofzik and Schule, 2017; Darios et al., 2020; Rickman et al., 2020). Phosphatidylethanolamine (PE) is a glycerophospholipid that, together with phosphatidylcholine, makes up more than 50% of the total phospholipids in eukaryotic cell membranes (McMaster, 2018). PE is particularly enriched in the brain where it constitutes ∼45% of the phospholipid fraction. PE is the product of two major biochemical processes: the CDP-ethanolamine pathway (Kennedy pathway) and the decarboxylation of phosphatidylserine in mitochondria (Vance, 2015; McMaster, 2018). CTP: phosphoethanolamine cytidylyltransferase, encoded by PCYT2, performs a crucial role within the CDP-ethanolamine pathway. It catalyses the conversion of CTP and phosphoethanolamine into CDP-ethanolamine, an intermediate that is subsequently converted into PE by ethanolamine phosphotransferase (McMaster, 2018). Here, we report an additional patient, in this independent report on PCYT2, with a complex HSP caused by compound heterozygous mutations in PCYT2, highlighting a marked broadening of the phenotypical spectrum. The patient under study was born from healthy non-consanguineous parents. All procedures were carried out as part of routine clinical care. Written informed consent was obtained from all participants for genetic studies. Whole-exome sequencing was performed within the PREPARE consortium (https://www.prepare-ataxia.com) on genomic DNA of the index patient and was performed using Illumina Nextera Rapid Capture Expanded exome kit for exome enrichment and Illumina HiSeq2000 platform for sequencing. Sequence reads were aligned to the UCSC Genome Browser hg19 reference sequence and the data were imported and annotated in the GENESIS (Gem.app) platform, a web-based tool for next generation sequencing data analysis (http://thegenesisprojectfoundation.org/) (Gonzalez et al., 2015). We identified compound heterozygous mutations in PCYT2 (NM_001184917.1): a missense c.736G>A (p.Gly246Arg) and a frameshift c.524_527del (p.Asp175Valfs*109) (Fig. 1A). The PCYT2 variants revealed by exome sequencing were validated by Sanger sequencing in the index patient and both parents, showing a trans orientation of the variants in the index patient (Fig. 1). No additional bi-allelic PCYT2 variants were identified in 1700 HSP/ataxia samples of the PREPARE consortium, which likely makes PCYT2-related HSP/spastic ataxia a rare entity. Patients characteristics and phenotypical correlations. (A) Pedigree of affected patient and the healthy non-consanguineous parents. (B) MRI at age 29. Left: Two FLAIR-sequence images showing no apparent abnormalities. Right: T2-sequence showing on a sagittal plane cerebellar atrophy and mild global cortical atrophy. (C) Schematic representation of phenotypic correlations and severity of PCYT2 (Vaz et al., 2019), PCYT2 (this case description), PCYT1 and EPT1 associated disorders. Patients characteristics and phenotypical correlations. (A) Pedigree of affected patient and the healthy non-consanguineous parents. (B) MRI at age 29. Left: Two FLAIR-sequence images showing no apparent abnormalities. Right: T2-sequence showing on a sagittal plane cerebellar atrophy and mild global cortical atrophy. (C) Schematic representation of phenotypic correlations and severity of PCYT2 (Vaz et al., 2019), PCYT2 (this case description), PCYT1 and EPT1 associated disorders. The currently 45-year-old male index patient has a history of progressive gait instability, appendicular ataxia, anosmia, visual and speech disturbances. Gait instability presented as the first symptom at the age of 20 months after initial acquisition of unassisted walking. Further slow regression of ambulation occurred until wheelchair dependency at 38 years of age. Clinical examination is in line with a spastic paraplegia in combination with cerebellar and posterior column ataxia. There was an absence of frontal release signs and no extrapyramidal symptoms were noted. Speech disturbances appeared at 22 months of age and progressed to moderately intelligible cerebellar dysarthric speech at present. In secondary school he was noted to have anosmia. Visual disturbances (night and colour blindness) commenced at age of 18 years and the patient was later diagnosed with rod-cone dystrophy as seen on fundoscopy and flash-electroretinography. Additional findings are scoliosis and a high arched palate. Normal intellectual development and absence of epilepsy are of particular interest. Brain MRI findings at the age of 29 showed markedly cerebellar but only discrete cerebral atrophy in the absence of other structural abnormalities or white matter lesions (Table 1 and Fig. 1B). Clinical findings Phenotypical presentation (age at evaluation: 45 years) Global hyperreflexia, plantar reflex in extension bilaterally Hypertonia lower limbs Proximal weakness lower limbs Distally preserved Truncal and appendicular ataxia Saccadic ocular pursuit, no nystagmus Dysarthria: moderately intelligible speech Loss of vibration sense lower limbs Mild loss of proprioception at the feet Impaired central visual acuity: best corrected Snellen visual acuity of 0.25 in right and left eye. Night vision deficit Preserved limits of the peripheral visual field on Goldmann perimetry Colour vision: severely impaired Fundoscopy: pale optic discs and narrowed retinal arteries bilaterally; no retinal bone spiculae Flash-electroretinogram: rod-cone retinal dystrophy (first documented at age 22; confirmed and stable at age 28 and 34) Preserved limits of the peripheral visual field on Goldmann perimetry Phenotypical presentation (age at evaluation: 45 years) Global hyperreflexia, plantar reflex in extension bilaterally Hypertonia lower limbs Proximal weakness lower limbs Distally preserved Truncal and appendicular ataxia Saccadic ocular pursuit, no nystagmus Dysarthria: moderately intelligible speech Loss of vibration sense lower limbs Mild loss of proprioception at the feet Impaired central visual acuity: best corrected Snellen visual acuity of 0.25 in right and left eye. Night vision deficit Preserved limits of the peripheral visual field on Goldmann perimetry Colour vision: severely impaired Fundoscopy: pale optic discs and narrowed retinal arteries bilaterally; no retinal bone spiculae Flash-electroretinogram: rod-cone retinal dystrophy (first documented at age 22; confirmed and stable at age 28 and 34) Preserved limits of the peripheral visual field on Goldmann perimetry Clinical findings Phenotypical presentation (age at evaluation: 45 years) Global hyperreflexia, plantar reflex in extension bilaterally Hypertonia lower limbs Proximal weakness lower limbs Distally preserved Truncal and appendicular ataxia Saccadic ocular pursuit, no nystagmus Dysarthria: moderately intelligible speech Loss of vibration sense lower limbs Mild loss of proprioception at the feet Impaired central visual acuity: best corrected Snellen visual acuity of 0.25 in right and left eye. Night vision deficit Preserved limits of the peripheral visual field on Goldmann perimetry Colour vision: severely impaired Fundoscopy: pale optic discs and narrowed retinal arteries bilaterally; no retinal bone spiculae Flash-electroretinogram: rod-cone retinal dystrophy (first documented at age 22; confirmed and stable at age 28 and 34) Preserved limits of the peripheral visual field on Goldmann perimetry Phenotypical presentation (age at evaluation: 45 years) Global hyperreflexia, plantar reflex in extension bilaterally Hypertonia lower limbs Proximal weakness lower limbs Distally preserved Truncal and appendicular ataxia Saccadic ocular pursuit, no nystagmus Dysarthria: moderately intelligible speech Loss of vibration sense lower limbs Mild loss of proprioception at the feet Impaired central visual acuity: best corrected Snellen visual acuity of 0.25 in right and left eye. Night vision deficit Preserved limits of the peripheral visual field on Goldmann perimetry Colour vision: severely impaired Fundoscopy: pale optic discs and narrowed retinal arteries bilaterally; no retinal bone spiculae Flash-electroretinogram: rod-cone retinal dystrophy (first documented at age 22; confirmed and stable at age 28 and 34) Preserved limits of the peripheral visual field on Goldmann perimetry The CDP-ethanolamine pathway is a multistep process that uses ethanolamine to form PE and it has been directly implicated in HSP in two separate instances: EPT1 and PCYT2 (Ahmed et al., 2017; Vaz et al., 2019). Although the phenotypes associated with EPT1 and PCYT2 mutations fall within the broader spectrum of complex HSPs, there are some notable differences between the reported phenotypes. Before, intellectual disability was invariably present in PCYT2 patients and ranged from mild to severe and was typically complicated by epilepsy. In EPT1 patients, the intellectual disability is usually mild. Conversely, the patient in the current study was shown to have normal intellectual development and no history of epileptic seizures. Similar to the EPT1 patients, our patient shows development of dysarthric speech and palate abnormalities. Interestingly, recessive mutations in PCYT1A (also part of the CDP-ethanolamine pathway converting phosphocholine into CDP-choline) are causal in spondylometaphyseal dysplasia with cone-rod dystrophy and isolated retinal dystrophy (Hoover-Fong et al., 2014; Testa et al., 2017). Ophthalmic phenotypes seem to be a common feature of disruption in the Kennedy pathway; for instance, the rod-cone dystrophy in our patient, has been noted in several of the EPT1 patients. In the previous report, poor visual acuity was noted in three of the reported PCYT2 patients without a clear cause described. Further overlap can be observed when considering the skeletal abnormalities associated with PCYT1A mutations. Patients reported with PCYT2 and EPT1 mutations were all reported with short stature (standard deviation < −0.94). Moreover, while our patient is the only PCYT2 patient with scoliosis, it has been reported for several PCYT1A patients (Yamamoto et al., 2014). The patient in the current study clearly demonstrates that phenotypes associated with EPT1, PCYT1A and PCYT2 mutations overlap to a more substantial degree than previously reported. As such, dysregulation within the Kennedy pathway results in a broad phenotypic spectrum and can include variable combinations of spastic paraplegia, epilepsy, neurodevelopmental delay, ophthalmic and skeletal phenotypes (Fig. 1C). The data that support the findings of this study are available from the corresponding author, upon reasonable request. European Union’s Horizon 2020 Research and Innovation Program under the ERA-NET Co fund action No. 643578 under the frame of the E-Rare-3 network PREPARE, grant779257 Solve-RD from the Horizon 2020 Research and Innovation Programme (to M.S. and as an associated partner to J.B). D.B. is supported by a DOCPRO4 Antwerp University Research Fund (BOF) project grant under agreement number DOCPRO2016–33497. P.V.D. holds a senior clinical investigatorship of FWO-Vlaanderen and is supported by the E. von Behring Chair for Neuromuscular and Neurodegenerative Disorders, the ALS Liga België and the KU Leuven funds “Een Hart voor ALS”, “Laeversfonds voor ALS Onderzoek” and the “Valéry Perrier Race against ALS Fund”. J.B. is supported by a Senior Clinical Researcher mandate of the Research Fund - Flanders (FWO) under grant agreement number 1805016N. Several authors of this publication are member of the European Reference Network for Rare Neuromuscular Diseases (ERN EURO-NMD) and of the European Reference Network for Rare Neurological Diseases (ERN-RND). The authors report no competing interests.
No takes yet. Share an insight, caveat, or question.
Winter et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: